NCT03002935View on ClinicalTrials.gov

A Safety Study of Orally Administered BPM31510 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Healthy
Interventions
DRUG

BPM31510 Oral Nanosuspension 4%

Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)

Trial Locations (1)

07724

Clinilabs Inc., Eatontown

All Listed Sponsors
lead

BPGbio

INDUSTRY

NCT03002935 - A Safety Study of Orally Administered BPM31510 in Healthy Subjects | Biotech Hunter | Biotech Hunter